What smart money is saying about Galderma
4 funds in our archive have pitched Galderma — most recently Sands Capital Global Growth in December 2025.
Galderma Group AG is engaged in cosmetic industry. Its segment includes Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Fund coverage · 4 theses
- Sands Capital Global GrowthDecember 2025
Galderma is a dermatology leader with outperforming products like Nemluvio and Relfydess, rising guidance, and underappreciated share gain and revenue potential.
Read the full thesis - Sands Capital Global GrowthSeptember 2025
Galderma is well-positioned for long-term growth in the dermatology market, leveraging its strong brand, innovative products, and direct-to-consumer revenue model.
Read the full thesis - Sands Capital International GrowthJune 2025
Galderma is a leading Swiss dermatology company positioned for long-term above-average earnings growth due to its strong market presence, innovative products, and focus on high-margin injectables and therapeutics.
Read the full thesis - Platinium AMDecember 2024
Galderma is our largest single holding, showing strong growth in injectable aesthetics and skincare, with the potential for significant earnings boost from its newly approved eczema drug, Nemolizumab, set to launch in 2025.
Read the full thesis
Read every full thesis on Galderma
Unlock all 4 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→